- Home
- CHRS vs EBMT Comparison
CHRS vs EBMT Comparison
Compare CHRS & EBMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- EBMT
- Stock Information
- Founded
- CHRS 2010
- EBMT 1922
- Country
- CHRS United States
- EBMT United States
- Employees
- CHRS N/A
- EBMT N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- EBMT Major Banks
- Sector
- CHRS Health Care
- EBMT Finance
- Exchange
- CHRS Nasdaq
- EBMT Nasdaq
- Market Cap
- CHRS 134.4M
- EBMT 139.5M
- IPO Year
- CHRS 2014
- EBMT N/A
- Fundamental
- Price
- CHRS $1.07
- EBMT $18.02
- Analyst Decision
- CHRS Strong Buy
- EBMT
- Analyst Count
- CHRS 4
- EBMT 0
- Target Price
- CHRS $5.38
- EBMT N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- EBMT 29.0K
- Earning Date
- CHRS 03-12-2025
- EBMT 01-28-2025
- Dividend Yield
- CHRS N/A
- EBMT 3.16%
- EPS Growth
- CHRS N/A
- EBMT N/A
- EPS
- CHRS N/A
- EBMT 1.24
- Revenue
- CHRS $304,340,000.00
- EBMT $80,696,000.00
- Revenue This Year
- CHRS $2.07
- EBMT N/A
- Revenue Next Year
- CHRS N/A
- EBMT $6.33
- P/E Ratio
- CHRS N/A
- EBMT $14.53
- Revenue Growth
- CHRS 44.19
- EBMT N/A
- 52 Week Low
- CHRS $0.66
- EBMT $12.32
- 52 Week High
- CHRS $2.65
- EBMT $18.37
- Technical
- Relative Strength Index (RSI)
- CHRS 39.03
- EBMT 78.44
- Support Level
- CHRS $1.06
- EBMT $14.87
- Resistance Level
- CHRS $1.16
- EBMT $15.47
- Average True Range (ATR)
- CHRS 0.08
- EBMT 0.54
- MACD
- CHRS 0.00
- EBMT 0.34
- Stochastic Oscillator
- CHRS 5.56
- EBMT 90.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.